Abiopharma

(100% Positive) SYSCO CORP (SYY) Announces Business Combination

New Form 424B2 - UBS AG <b>Filed:</b> 2026-08-20 <b>AccNo:</b> 0001839882-26-040796 <b>Size:</b> 683 KB

(80% Positive) CARDIO DIAGNOSTICS HOLDINGS, INC. (CDIO) Files Form 8-K

Sysco Announces Strategic Board Appointments and AI Transformation Initiatives Intended to Accelerate Growth, Long-Term Value Creation

New Form 424B2 - JPMORGAN CHASE & CO <b>Filed:</b> 2026-08-20 <b>AccNo:</b> 0001918704-26-024340 <b>Size:</b> 625 KB

General Announcement: UPDATE ON THE APPLICATION IN RELATION TO THE RESUMPTION OF TRADING PROPOSAL

(99% Neutral) NEXTTRIP, INC. (NTRP) Files Form 8-K

New Form 424B2 - BARCLAYS BANK PLC <b>Filed:</b> 2026-08-20 <b>AccNo:</b> 0001918704-26-024339 <b>Size:</b> 389 KB

New Form FWP - MORGAN STANLEY <b>Filed:</b> 2026-08-20 <b>AccNo:</b> 0001839882-26-040794 <b>Size:</b> 99 KB

bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026

Nuvation Bio Inc. - Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma

New Form 424B2 - UBS AG <b>Filed:</b> 2026-08-20 <b>AccNo:</b> 0001839882-26-040793 <b>Size:</b> 788 KB

(99% Neutral) VISIONWAVE HOLDINGS, INC. (VWAV) Announces Business Combination

Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium

Alzamend Neuros Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC